HK Stock Market Move | SKB BIO(06990) rose by over 5% in response to the payment of related amounts by Yiling Pharmaceutical in accordance with the settlement reached.

SKB BIO (06990) rose more than 5%, up 5.07% at the time of publication, to 414.4 Hong Kong dollars, with a turnover of 63.3357 million Hong Kong dollars. On the news front, on June 12, SKB BIO issued an announcement regarding the settlement agreement between the company and Suzhou Yilian Biopharmaceutical Co., Ltd. (Yilian Biopharmaceutical), Dr. Xue Tongtong, Dr. Xiao Liang, and Dr. Cai Jiaqiang. According to the settlement agreement reached, the company has recently received 602.5 million yuan from Yilian Biopharmaceutical for the income sharing of YL201. By the fiscal year 2026 and as of the date of this announcement, the company has received a total of 702.7 million yuan from Yilian Biopharmaceutical for the payments made according to the settlement agreement (including the aforementioned 602.5 million yuan).